a:5:{s:8:"template";s:3561:"<!DOCTYPE html>
<html lang="en">
<head>
<meta content="width=device-width, initial-scale=1.0" name="viewport">
<meta charset="utf-8">
<title>{{ keyword }}</title>
<style rel="stylesheet" type="text/css">body,div,footer,header,html,p,span{border:0;outline:0;font-size:100%;vertical-align:baseline;background:0 0;margin:0;padding:0}a{text-decoration:none;font-size:100%;vertical-align:baseline;background:0 0;margin:0;padding:0}footer,header{display:block} .left{float:left}.clear{clear:both}a{text-decoration:none}.wrp{margin:0 auto;width:1080px} html{font-size:100%;height:100%;min-height:100%}body{background:#fbfbfb;font-family:Lato,arial;font-size:16px;margin:0;overflow-x:hidden}.flex-cnt{overflow:hidden}body,html{overflow-x:hidden}.spr{height:25px}p{line-height:1.35em;word-wrap:break-word}#floating_menu{width:100%;z-index:101;-webkit-transition:all,.2s,linear;-moz-transition:all,.2s,linear;transition:all,.2s,linear}#floating_menu header{-webkit-transition:all,.2s,ease-out;-moz-transition:all,.2s,ease-out;transition:all,.2s,ease-out;padding:9px 0}#floating_menu[data-float=float-fixed]{-webkit-transition:all,.2s,linear;-moz-transition:all,.2s,linear;transition:all,.2s,linear}#floating_menu[data-float=float-fixed] #text_logo{-webkit-transition:all,.2s,linear;-moz-transition:all,.2s,linear;transition:all,.2s,linear}header{box-shadow:0 1px 4px #dfdddd;background:#fff;padding:9px 0}header .hmn{border-radius:5px;background:#7bc143;display:none;height:26px;width:26px}header{display:block;text-align:center}header:before{content:'';display:inline-block;height:100%;margin-right:-.25em;vertical-align:bottom}header #head_wrp{display:inline-block;vertical-align:bottom}header .side_logo .h-i{display:table;width:100%}header .side_logo #text_logo{text-align:left}header .side_logo #text_logo{display:table-cell;float:none}header .side_logo #text_logo{vertical-align:middle}#text_logo{font-size:32px;line-height:50px}#text_logo.green a{color:#7bc143}footer{color:#efefef;background:#2a2a2c;margin-top:50px;padding:45px 0 20px 0}footer .credits{font-size:.7692307692em;color:#c5c5c5!important;margin-top:10px;text-align:center}@media only screen and (max-width:1080px){.wrp{width:900px}}@media only screen and (max-width:940px){.wrp{width:700px}}@media only screen and (min-width:0px) and (max-width:768px){header{position:relative}header .hmn{cursor:pointer;clear:right;display:block;float:right;margin-top:10px}header #head_wrp{display:block}header .side_logo #text_logo{display:block;float:left}}@media only screen and (max-width:768px){.wrp{width:490px}}@media only screen and (max-width:540px){.wrp{width:340px}}@media only screen and (max-width:380px){.wrp{width:300px}footer{color:#fff;background:#2a2a2c;margin-top:50px;padding:45px 0 20px 0}}@media only screen and (max-width:768px){header .hmn{bottom:0;float:none;margin:auto;position:absolute;right:10px;top:0}header #head_wrp{min-height:30px}}</style>
</head>
<body class="custom-background">
<div class="flex-cnt">
<div data-float="float-fixed" id="floating_menu">
<header class="" style="">
<div class="wrp side_logo" id="head_wrp">
<div class="h-i">
<div class="green " id="text_logo">
<a href="{{ KEYWORDBYINDEX-ANCHOR 0 }}">{{ KEYWORDBYINDEX 0 }}</a>
</div>
<span class="hmn left"></span>
<div class="clear"></div>
</div>
</div>
</header>
</div>
<div class="wrp cnt">
<div class="spr"></div>
{{ text }}
</div>
</div>
<div class="clear"></div>
<footer>
<div class="wrp cnt">
{{ links }}
<div class="clear"></div>
<p class="credits">
{{ keyword }} 2022</p>
</div>
</footer>
</body>
</html>";s:4:"text";s:23199:"Tomivosertib is being evaluated in KICKSTART, eFFECTOR&#x27;s randomized, double-blind, placebo-controlled Phase 2b study in non-small cell lung cancer (&quot;NSCLC&quot;) in combination with pembrolizumab. DrugBank Accession Number. Identification. Our study provides pre-clinical evidence to initialize clinical trials for gastric cancer using tomivosertib in combination with chemotherapy. If results from the KICKSTART trial are clinically and statistically significant, the company plans to explore the potential for accelerated approval with the FDA. This study will evaluate the safety and antitumor activity of tomivosertib versus placebo in subjects . The present compilation provides a succinct review of the current state of development of pyridone-aminal-derived Mnk . It potentially results in decreased tumor cell proliferation and tumor growth. eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced publication in the peer reviewed journal Nature Medicine of preclinical research demonstrating that tomivosertib (eFT508), the company&#x27;s oral, selective, small molecule inhibitor of MNK1/2, selectively inhibits expression of the programed-death . eFFECTOR&#x27;s lead product candidate, tomivosertib, is a MNK inhibitor currently being . Back to Tomivosertib. Background. The success of tomivosertib reflects the powerful advantages of FBDD in rapid identification of selective lead compounds, and provided important guidance for medicinal chemists to carry out FBDD. NCT04261218. Enrollment in SU2C Breast Cancer Trial continues: Tomivosertib is being evaluated in an ongoing Phase 2a clinical trial in patients with metastatic breast cancer in combination with paclitaxel chemotherapy in a study led by Professor Nahum Sonenberg Ph.D., Gilman Cheney Chair in Biochemistry at McGill University. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines. Tomivosertib is also currently being evaluated in two additional Phase 2 combination trials with checkpoint inhibitors targeting PD-1 or PD-L1, including a trial (NCT03258398) in patients with . . Protocol No. This work was supported by the National Nature Science Foundation of China (grants 81872462 and 81972772) and the Clinical Trial Supporting Foundation of Tianjin Medical University Cancer Institute &amp; Hospital (grant C1707). This study will evaluate the safety and antitumor activity of tomivosertib versus placebo in subjects . Nave mice were trained for 1 trial, and then 2 baseline trials were conducted and scores for both trials were averaged. In December 2021, Biotheus Inc. announced that its proprietary anti-PD-L1/TGF- bifunctional therapeutic, named PM8001, has been approved by the USFDA (United States Food and Drug Administration . Compensation included. Tomivosertib, an inhibitor of MNK 1/2, works at multiple points in the cancer immunity cycle, and has demonstrated efficacy in a Phase 2 clinical trial in patients who progressed on checkpoint . Principal Investigator Tomivosertib (10 mg/kg i.p ~50 L) or vehicle was then injected, and 1 h later all mice were tested twice more, and their scores were averaged. A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L) . Phase: III. Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC). - Any illness, medical condition, organ system dysfunction, or social situation, . Generic Name. . The first patient was dosed in the phase 2b KICKSTART clinical trial from eFFECTOR Therapeutics, Inc. in early June. It is one of the first two Mnk inhibitors that entered clinical trials, and has displayed momentous activity against several solid and hematological cancers. &quot;The TNBC trial will expand the current tomivosertib Phase 2 clinical trial program, allowing eFFECTOR to explore a combination with KEYTRUDA for an indication in which neither drug is yet approved,&quot; said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.&quot;Based on preclinical studies showing tomivosertib has substantial immunomodulatory activity and synergizes with . eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity . Drugs; NCT03690141: An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC) Tomivosertib (DB15219) Interested in using DrugBank in a commercial product . These results prompted the advancement of CA-170 to human clinical trials. Enrollment in SU2C Breast Cancer Trial continues: Tomivosertib is being evaluated in an ongoing Phase 2a clinical trial in patients with metastatic breast cancer in combination with paclitaxel chemotherapy in a study led by Professor Nahum Sonenberg Ph.D., Gilman Cheney Chair in Biochemistry at McGill University. The company&#x27;s research program currently has two novel drug candidates undergoing clinical trials. The trial will enroll up to 45 patients with an Eastern Cooperative Oncology Group (ECOG) performance .  SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (&quot;STRIs&quot;) for the treatment of cancer, today reported positive interim results of the company&#x27;s ongoing Phase 1/2 clinical trial of eIF4A inhibitor . eFFECTOR&#x27;s lead product candidate, tomivosertib, is a MNK . Zotatifin Update 3112 Background: Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response represents a major challenge. Tomivosertib is being evaluated in KICKSTART, eFFECTOR&#x27;s randomized, double-blind, placebo-controlled Phase 2b study in non-small cell lung cancer (&quot;NSCLC&quot;) in combination with pembrolizumab. Tomivosertib (eFT508) is one of the molecules with such scaffold. Sasikumar et al. The study drug, tomivosertib, works by inhibiting the activity of proteins in a pathway that allow tumor cells to grow and go unnoticed by your immune system. A Phase III Clinical Trial for Test Use and Document Creation Only. mi. This trial is sponsored by a grant from the Defense Advanced Research Projects Agenda (DARPA) and is being . The researchers also found that Tomivosertib synergistically enhances the anti-leukemic effects of Venetoclax against AML cells in vitro. Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) NCT04622007. Tomivosertib (formerly eFT 508) is a highly selective, orally available, small molecule inhibitor of MNK1 and MNK2, . In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022. . Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial . If results from the KICKSTART trial are clinically . Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. SAN DIEGO, July 27, 2018 (GLOBE NEWSWIRE)  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company&#x27;s oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved . Each of eFFECTOR&#x27;s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. About UC Irvine Clinical Trials. that together control tumor growth, survival and immune evasion. Finally, we demonstrate that the in vitro functional and mechanism observations are translatable to in vivo gastric cancer model in mice. Tomivosertib (T), a potent and highly selective inhibitor of the immunosuppressive kinases MNK-1 and 2, blocks expression of checkpoint proteins PD-1, PD-L1, and LAG-3 as well as immunosuppressive cytokines IL-6 and IL-8 . eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity Our trial will determine if the potent MNK inhibitor, tomivosertib, controls tumor growth either directly or by enhancing anti-tumor immunity. Clinical trial of BAY 1143269 as a combination therapy with docetaxel in NSCLC was terminated due to project prioritization. The researchers also found that Tomivosertib synergistically enhances the anti-leukemic effects of Venetoclax against AML cells in vitro. Ph2 Tomivosertib+Anti-PD-L1 NSCLC. Tomivosertib (10 mg/kg i.p ~50 L) or vehicle was then injected, and 1 h later all mice were tested twice more, and their scores were averaged. : EFT508-0011. We are currently investigating zotatifin in ongoing clinical trials for solid tumors and as a potential host . Pending positive results from the KICKSTART Phase 2b clinical trial, the company plans to advance tomivosertib into Phase 3 registration trials. &quot;We observed in our phase 2a trial of tomivosertib in combination with . An upcoming Phase 2 trial will evaluate a combination of the immunotherapies Keytruda (pembrolizumab) and tomivosertib (eFT508) as a treatment for triple-negative breast cancer patients whose disease has spread to other regions, or metastasized.. As part of a new collaboration between eFFECTOR Therapeutics and Merck (known as MSD outside the U.S. and Canada), the trial will test the . we may use our capital resources sooner than expected and they may be insufficient to allow clinical trial readouts; regulatory developments in the United States and foreign countries . Tomivosertib (eFT-508) For research use only. Each entry includes links to find associated clinical trials. Our lead product candidate, tomivosertib, is an oral small molecule inhibitor of MNK. It is scheduled to be annotated soon. DB15219. Zotatifin is a potent and sequence-selective small molecule inhibitor of eIF4A that is designed to supress expression of a network of cancer driving proteins, including Cyclins D and E, CDKs 2, 4 and 6 and select RTKs as well as KRAS. &quot;2021 was a momentous year for eFFECTOR, as we advanced both our clinical stage assets, tomivosertib and zotatifin, into Phase 2 trials and raised additional capital with our debut as a public . A clinical trial for an investigational respiratory syncytial virus (RSV) vaccine combined with an approved flu vaccine for older adults. A Phase 2 clinical trial evaluating eFFECTOR Therapeutics&#x27; investigational therapy tomivosertib (eFT508), for men with advanced castrate-resistant prostate cancer (CRPC) who failed to respond to androgen receptor signaling (ARS) inhibitors, has begun dosing patients.. Pending positive results from the KICKSTART Phase 2b clinical trial, the company plans to advance tomivosertib into Phase 3 registration trials. Tomivosertib, also known as eFT-508, is a potent, highly selective and orally bioavailable MNK1 and MNK2 inhibitor that is currently under investigation in Phase 1/2 clinical trials for the treatment of patients with advanced solid tumors and lymphomas . Tomivosertib is now in phase 2 clinical trials. A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy: Actual Study Start Date : June 2, 2021: Estimated Primary Completion Date : March 15, 2024: Estimated Study Completion Date : This is a multicenter, open-label trial to evaluate the safety, pharmacodynamics (PD), pharmacokinetics (PK), and efficacy of tomivosertib in combination with paclitaxel in patients with advanced breast cancer (ABC) of any subtype. A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line . We thank Jiangsu HengRui Medicine Co., China, for kindly providing the anti-PD-1 antibody camrelizumab. Tomivosertib (eFT508): eFFECTOR&#x27;s wholly-owned, highly selective MNK inhibitor designed to enhance anti-tumor activity by stimulating activation, . Tomivosertib (eFT508) is a novel small-molecule inhibitor of MNK that delays T cell exhaustion/dysfunction and is being developed in combination with pembrolizumab in 1L NSCLC patients with PD-L1  1%. Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. eFFECTOR is supplying . Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART) . The trial (NCT03690141), currently recruiting participants, will evaluate the safety, tolerability and antitumor activity of . Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial . Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. including clinical trial and manufacturing delays; our ability to access the LPC facility is subject to certain conditions; our . Multiple Myeloma. from . Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure. eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity we may use our capital resources sooner than expected and they may be insufficient to allow clinical trial readouts; regulatory developments in the United States and foreign countries . Each entry includes links to find associated clinical trials. Tomivosertib Completed Phase 2 Trials for Castration Resistant Prostate Cancer Treatment. Status: Enrolling . Tomivosertib (eFT508): eFFECTOR&#x27;s wholly-owned, highly selective MNK inhibitor designed to enhance anti-tumor immune activity by stimulating activation, . Nave mice were trained for 1 trial, and then 2 baseline trials were conducted and scores for both trials were averaged. Home . The time until each animal fell was recorded for each trial. An upcoming Phase 2 trial will evaluate a combination of the immunotherapies Keytruda (pembrolizumab) and tomivosertib (eFT508) as a treatment for triple-negative breast cancer patients whose disease has spread to other regions, or metastasized.. As part of a new collaboration between eFFECTOR Therapeutics and Merck (known as MSD outside the U.S. and Canada), the trial will test the . Annapolis, MD. This is an open-label, Phase 1-2, first-in-human study for CX-2029 in subjects with metastatic or locally advanced unresectable solid tumors or Diffuse large B-cell lymphoma (DLBCL) without approved life-prolonging . This Phase 2 Open-label Study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of tomivosertib (eFT508) in Patients with advanced CR. KICKSTART is a randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and safety of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA)-approved PD-1 inhibitor, as frontline combination therapy or as an extension of frontline therapy at the first radiographic progression of . PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL. Current Clinical Trials; EFT508-0011; Navigation. The randomized trial will treat patients who have non-small cell lung cancer (NSCLC) with a combination of tomivosertib and Keytruda (pembrolizumab). Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy. Previously received investigational product in a clinical trial within 30 days or within 5 elimination half-lives (whichever is longer) prior to the start of Tomivosertib (eFT-508), or is planning to take part in another clinical trial while participating in this study; SAN DIEGO, July 27, 2018  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company&#x27;s oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved anti-PD-1 or anti . Tomivosertib. 01 Apr 2021 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT04622007) Lung Cancer Studies . Title Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-L1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-L1 Therapy. The purpose of the study is to see whether tomivosertib in combination with pembrolizumab treatment slows down the growth of cancers. eFFECTOR is supplying . The goals of the trial include not only routine monitoring for clinical benefit and toxicity but also to employ techniques not previously used in clinical trials to understand the details of drug action in The leading candidate, tomivosertib, is the subject of two Phase 2 studies featuring two . SAN DIEGO, CA, USA I July 27, 2018 I eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced that it has dosed the first patient in a Phase 2 clinical trial of eFT508 (tomivosertib), the company&#x27;s oral, small molecule inhibitor of MNK1/2, added on to patients already receiving an FDA-approved anti-PD-1 . Status: Enrolling Updated: 12/31/1969 Anne Arundel Medical Center. Enrollment in SU2C Breast Cancer Trial continues: Tomivosertib is being evaluated in an ongoing Phase 2a clinical trial in patients with metastatic breast cancer in combination with paclitaxel . Kickstart is a double-blind, randomized, multi-center Phase 2b clinical trial. Researchers in this study believe that Tomivosertib, a highly selective MNK1/2 inhibitor (currently undergoing clinical trials for the treatment of patients with advanced solid tumors and lymphomas), . 01 Apr 2021 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT04622007) Tomivosertib (eFT508): eFFECTOR&#x27;s wholly-owned, highly selective MNK inhibitor designed to enhance anti-tumor immune activity by stimulating activation, delaying exhaustion, and prolonging the memory of T cells. Tomivosertib. The study drug, tomivosertib, works by inhibiting the activity of proteins in a pathway that allow tumor cells to grow and go unnoticed by your immune system. . . This Phase 2, open-label study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of Tomivosertib (eFT-508) in subjects who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no . In addition, zotatifin is being evaluated in a Phase 1b clinical trial as an antiviral agent in patients with mild to moderate COVID-19 infections. Tomivosertib (formerly eFT 508) is a highly selective, orally available, small molecule inhibitor of MNK1 and MNK2, . Previously received investigational product in a clinical trial within 30 days or within 5 elimination half-lives (whichever is longer) prior to the start of Tomivosertib (eFT-508), or is planning to take part in another clinical trial while participating in this study; . The trial will enroll up to 45 patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 with any breast cancer (BC) subtype . The purpose of the study is to see whether tomivosertib in combination with pembrolizumab treatment slows down the growth of cancers. One cohort will enroll patients with PD-L1 1% NSCLC who have . This is a multicenter, open-label trial to evaluate the safety, pharmacodynamics (PD), pharmacokinetics (PK), and efficacy of tomivosertib in combination with paclitaxel in patients with advanced breast cancer (ABC) of any subtype. SAN DIEGO and REDWOOD CITY, Calif., June 05, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (&quot;STRIs&quot;) for the treatment of cancer, today reported positive interim results of the company&#x27;s ongoing Phase 1/2 clinical trial of eIF4A inhibitor zotatifin in patients with solid tumors that showed . This trial; Search. Researchers in this study believe that Tomivosertib, a highly selective MNK1/2 inhibitor (currently undergoing clinical trials for the treatment of patients with advanced solid tumors and lymphomas), . - Concurrent participation in another therapeutic clinical trial. This drug entry is a stub and has not been fully annotated. Dr. Sikorski, who played a similar role for eFFECTOR in 2020, has a deep knowledge of the company&#x27;s STRI development programs and will lead clinical development of both tomivosertib and zotatifin. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance. &quot;2021 was a momentous year for eFFECTOR, as we advanced both our clinical stage assets, tomivosertib and zotatifin, into Phase 2 trials and raised additional capital with our debut as a public . SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (&quot;STRIs&quot;) for the treatment of cancer, announced today the publication of data highlighting the role of eukaryotic translation initiation factor 4E (&quot;eIF4E&quot;), in the peer-reviewed journal Cell Reports. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. The time until each animal fell was recorded for each trial. Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. eIF4E is a component of the eIF4F . Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance. A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With . ";s:7:"keyword";s:27:"tomivosertib clinical trial";s:5:"links";s:1290:"<ul><li><a href="https://tenderbit.es/ees/16757077ffa5f8a2">Discord Shutting Down 2022 Rickroll</a></li>
<li><a href="https://tenderbit.es/ees/16755957ffa5f8f7fb1840b2be65">Frank Faylen Net Worth</a></li>
<li><a href="https://tenderbit.es/ees/16756268ffa5f8db144180ce0bb9341d3de3e">Brave Cursed Cake Recipe</a></li>
<li><a href="https://tenderbit.es/ees/16754434ffa5f82e8026baf98b6ee8">What Caused The Collapse Of Reconstruction</a></li>
<li><a href="https://tenderbit.es/ees/16755895ffa5f88f">Why Does Darcy Pay Wickham To Marry Lydia</a></li>
<li><a href="https://tenderbit.es/ees/16756419ffa5f8ab">Franz Klammer Nickname</a></li>
<li><a href="https://tenderbit.es/ees/16754849ffa5f809e8a0c4d552785de110">Country Way Sprayer Parts</a></li>
<li><a href="https://tenderbit.es/ees/16754696ffa5f832533">Frederick County Md Snow Totals</a></li>
<li><a href="https://tenderbit.es/ees/16754929ffa5f81909358617bdc00742e66f1">Best Live Albums Of All Time</a></li>
<li><a href="https://tenderbit.es/ees/16755894ffa5f81d8814be">Alton Telegraph Police Blotter October 2020</a></li>
<li><a href="https://tenderbit.es/ees/16755871ffa5f86f9353fabec3aa">Dochodkova Reforma 2023</a></li>
<li><a href="https://tenderbit.es/ees/16757065ffa5f8237ea8b96cb671b9">Grace Vanderwaal Tina Vanderwaal</a></li>
</ul>";s:7:"expired";i:-1;}